David P. Bonita - 02 Jun 2022 Form 4 Insider Report for IMARA Inc. (ELVN)

Reporting relationship: Director, 10%+ Owner
Issuer ticker: ELVN
Reported as of: 02 Jun 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 03 Jun 2022, 20:18:19 UTC
Prior SEC filing: 16 May 2022
Next SEC filing: 13 Jun 2022
Source filing: View source filing
Reporting owner signature: /s/ Michael P. Gray, Attorney-in-Fact

Key filing fact

David P. Bonita filed Form 4 for IMARA Inc. (ELVN) on 03 Jun 2022.

Key facts

This page summarizes David P. Bonita's Form 4 filing for IMARA Inc. (ELVN).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 03 Jun 2022, 20:18.

Change

Previous filing in this sequence was filed on 16 May 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ELVN holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 4,199,068
Date: 02 Jun 2022
Ownership: By OrbiMed Private Investments VII, LP
Footnotes: F1, F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ELVN transaction Derivative

Stock Options (Right to Buy)

Award

Transaction value: $0
Shares: +8,500
Change %
Price: $0.000000
Shares after: 8,500
Date: 02 Jun 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 8,500
Exercise price: $1.07
Footnotes: F3, F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

The Shares are held of record by OrbiMed Private Investments VII, LP ("OPI VII"). OrbiMed Capital GP VII LLC ("GP VII") is the general partner of OPI VII and OrbiMed Advisors LLC ("OrbiMed Advisors"), a registered investment adviser under the Investment Advisers Act, is the managing member of GP VII. GP VII and OrbiMed Advisors may be deemed to have voting and investment power over the securities held by OPI VII and may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the Shares held by OPI VII. The Reporting Person is a member of OrbiMed Advisors.

Footnote F2

The Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose.

Footnote F3

The option will vest on the first anniversary of the date of grant or, if earlier, the date of Imara's next annual meeting of stockholders following the date of grant.

Footnote F4

Pursuant to an agreement with OrbiMed Advisors and GP VII, the Reporting Person is obligated to transfer these securities, or the economic benefit thereof, to OrbiMed Advisors and GP VII, which will in turn ensure that such securities or economic benefits are provided to OPI VII.